New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 19, 2012
13:23 EDTEKDKQ, FB, CVSKodak extends printing relationship with CVS through 2016
Eastman Kodak Company (EKDKQ) announced late Friday that it will extend its relationship with CVS/pharmacy (CVS) through 2016. CVS/pharmacy operates 7,400 stores across the U.S. and is the largest customer of Kodak's Retail Systems Solutions business. CVS/pharmacy has over 15,000 Kodak Picture Kiosks in its stores. As part of this agreement, CVS/pharmacy will be upgrading and expanding its fleet of KODAK Adaptive Picture Exchange dry lab systems offerings. Following the positive customer response to the print from Facebook (FB) feature, CVS/pharmacy recently launched mobile printing from smartphones to the Kodak Kiosk. Because this new agreement resolves certain pre-chapter 11 issues between the two companies, it will be brought before the court for approval at a hearing scheduled for December 7.
News For EKDKQ;CVS;FB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 >>
November 20, 2015
16:02 EDTFBOptions Update; November 20, 2015
Subscribe for More Information
10:04 EDTFBActive equity options trading on open
Subscribe for More Information
November 19, 2015
11:15 EDTFBStocks with call strike movement; AMZN FB
Subscribe for More Information
09:34 EDTFBActive equity options trading on open
Active equity options trading on open: AAPL CHK BAC FB PFE MU GMCR AMZN NFLX BBY BABA CRM QCOM
06:38 EDTFBFacebook multiple 'has room to move higher,' says Citi
After analyzing Facebook's expense growth, Citi analyst Mark May says 2016 consensus estimates for the social network giant have 3%-6% potential upside. May believes the stock's multiple "has room to move higher" and keeps a Buy rating on Facebook with a $134 price target. He thinks expense growth in 2016 will range between high-30% and 50% and views consensus revenue forecasts as still too conservative.
November 18, 2015
16:44 EDTFBGoogle ad exec jumps to YouTube, Re/code says
Neal Mohan, previously Google's (GOOG) SVP for display and video advertising, has been appointed SVP of product for YouTube in a move signaling renewed efforts to combat Facebook (FB) video, reports Re/code, citing spokesperson statements. Paul Muret, currently head of analytics at Google, will succeed Mohan, and the company's analytics group will be folded into its display operations. Re/code notes that the analytics rollup may indicate Google sees measurement as "core" to its advertising business. Reference Link
15:40 EDTCVSCongressman says U.S. may need look at pharmacy competition, dealReporter says
Subscribe for More Information
14:20 EDTFBFacebook fundraising tool bears resemblance to Kickstarter, TechCrunch says
Subscribe for More Information
11:01 EDTCVSTarget says working with CVS team to secure regulatory approval for deal
Target (TGT) says "pleased" with progress to date of CVS (CVS) deal.
09:34 EDTFBActive equity options trading on open
Subscribe for More Information
05:55 EDTFBFacebook partners with Airtel Africa to bring free basics to 17 countries
In an announcement on Facebook, CEO Mark Zuckerberg said, "In South Africa , we announced with Airtel Africa that we will be bringing free basic services to all 17 countries where they operate. first launched in Zambia and today half of the 30 countries with Free Basics are in Africa. These new launches will bring free services to Burkina Faso, Chad, Gabon, Madagascar, Niger, Nigeria, Republic of the Congo, Sierra Leone and Uganda. We also recently partnered to launch a satellite to provide internet coverage to remote areas of Sub-Saharan Africa starting in 2016. We've also partnered with the Praekelt Foundation to give developers the tools they need to build free basic services to reach people just coming online. Connecting people across the African continent is critical to our mission. We're going to keep pushing forward to develop new ways to bring people online until the whole world is connected." Reference Link
November 17, 2015
16:01 EDTFBOptions Update; November 17, 2015
iPath S&P 500 VIX Short-Term Futures up 1.32 to 21.07. Option volume leaders: GE BAC AAPL FB NFLX SYF WMT CSCO MU SUNE VRX BABA AMZN HD FCX
10:17 EDTCVSHouse Judiciary Committee to hold a hearing
The Subcommittee on Regulatory Reform, Commercial and Antitrust Law holds a hearing entitled, "The State of Competition in the Pharmacy Benefit Manager and Pharmacy Marketplaces" with Vice President Bricker of Express Scripts and Senior Vice President Pons of CVS Health on November 17 at 3 pm. Webcast Link
09:35 EDTFBActive equity options trading on open: AAPL FB GE HD
Subscribe for More Information
November 16, 2015
16:00 EDTFBOptions Update; November 16, 2015
Subscribe for More Information
09:59 EDTFBOmega bought Valeant in Q3, sold some SuneEdison
Leon Cooperman's Omega Advisors gave a quarterly update on its stakes in a filing this morning, disclosing its positions as of September 30. NEW STAKES: Pfizer (PFE), Valeant (VRX) Walgreens Boots Alliance (WBA), TerraForm Global (GLBL), Cigna (CI). INCREASED STAKES: Google Class A (GOOGL), Facebook (FB), Delta Air Lines (DAL). DECREASED STAKES: SunEdison (SUNE), Shire (SHPG), Citi (C), KAR Auction (KAR), LyondellBasell (LYB). LIQUIDATED STAKES: McKesson (MCK), 21st Century Fox (FOXA), General Motors (GM), QEP Resources (QEP), eBay (EBAY).
09:37 EDTFBActive equity options trading on open
Active equity options trading on open: AAPL FB ORCL BAC SUNE FDX FCX EXPE NFLX MU AMZN INTC TSLA
09:06 EDTCVSDiplomat seen as compelling amid specialty pharmacy fallout
Shares of specialty pharmacy operator Diplomat Pharmacy (DPLO) and pharmacy benefit manager Express Scripts (ESRX) have each been knocked down by the negative news surrounding the sector amid the troubles faced by Valeant (VRX) and others, but an analyst at Leerink contends in a note to investors that the pullbacks in both stocks provide buying opportunities. BACKGROUND: Drugmaker Valeant and its prior specialty pharmacy partner, Philidor Rx Services, have been at the center of the firestorm engulfing the sector. Following claims that Philidor urged its employees to modify prescriptions to ensure more orders of Valeant-branded drugs rather than generics, as well as other allegations of wrongdoing, Express Scripts (ESRX) and peer CVS Health (CVS) terminated Philidor from their networks. The day after those termination announcements, Valeant said that it was severing all ties with Philidor and that the pharmacy planned to shut down operations as soon as possible, consistent with applicable laws. Valeant has subsequently said that Philidor has committed to cease operations by January 30, 2016, at the latest. More recently, Express Scripts, the nation's largest pharmacy benefit manager, announced that it stopped doing business with Linden Care, accusing it of being a "captive" pharmacy that dispenses mostly products made by Horizon Pharma (HZNP). In turn, Horizon called the idea that Linden Care is a captive pharmacy "entirely false," stating that "at best Express Scripts is being reckless in its allegations and at worse it is intentionally attempting to mislead investors." Express Scripts' move also impacted shares of Insys Therapeutics (INSY), which reportedly also used Linden Care to fulfill prescription for its drugs. DIPLOMAT LIKELY TO STAY IN-NETWORK: Leerink analyst David Larsen acknowledged that recent events indicate that Express Scripts appears to be evaluating certain retail pharmacies and their relationships with manufacturers, but he believes Diplomat's mix of drugs for diseases like multiple sclerosis, HIV, hepatitis C and cancer differentiate it as a "true" specialty pharmacy. Larsen does not think Diplomat is at risk of being excluded from the pharmacy networks of Express Scripts, CVS or UnitedHealth's (UNH) Optum, he tells investors. Larsen expects limited distribution agreements to stay an important channel strategy for drugmakers and believes these agreements are appropriate for high cost specialty drugs that require special handling and additional services to manage patient adherence. The analyst, who thinks Diplomat remains well positioned to deliver annual growth of over 30% in the next several years, keeps an Outperform rating on its shares. EXPRESS BUYING OPPORTUNITY: Larsen also thinks concerns around manufacturer and pharmacy relationships have put unwarranted pressure on shares of Express Scripts. He does not expect Express Scripts to disclose new lawsuits around rebate dollars owed over other manufacturer disputes and keeps an Outperform rating on the stock, which he views as having an "attractive" valuation. WHAT'S NOTABLE: Larsen also thinks that the specialty channel remains an opportunity for Walgreens Boots Alliance (WBA) and believes its proposed acquisition of Rite Aid (RAD) can strengthen its specialty offering. The analyst keeps an Outperform rating on Walgreens shares as well. PRICE ACTION: Over the last three months, Diplomat Pharmacy shares have declined 28%, Express Scripts has fallen 6% and Walgreens has dropped 14%.
06:18 EDTCVSDiplomat Pharmacy selloff brings 'compelling' entry point, says Leerink
Subscribe for More Information
November 15, 2015
17:54 EDTFBFacebook to expand use of 'Safety Check' feature in wake of Paris attacks
Facebook announced it will be expanding its use of "Safety Check," a feature allowing users of the social network who live in endangered areas of the world to let friends and family know they are safe. Traditionally limited to natural disasters, the policy change has been made in the wake of the terrorist attacks on Paris, France, during which the company turned on Safety Check for affected users. The move spurred both praise for quick action and criticism for not using the feature during other serious events such as Thursday's tragedy in Beirut, prompting Facebook to reconsider its use of the service. "Each time we have launched the tool, we've improved it... We are learning to make the tool and policies behind it better as we go -- and because Safety Check is a relatively new feature for us, we're still understanding how it can best be used... We talked with our employees on the ground, who felt that there was still a need that we could fill. So we made the decision to try something we've never done before: activating Safety Check for something other than a natural disaster... We want this tool to be available whenever and wherever it can help," explained the company.
1 | 2 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use